UPM Institutional Repository

Differential expression of GDF-15, PSAP, and COL6A1 in prostate cancer cells and TNM plot-based clinical tissue specimens of prostate cancer Adenocarcinoma


Citation

Kavousighahfarokhi, Negin and Rosli@pazli, Ayuni Syafiqah and Zainal, Nur Ariesya Aquila and Roslan, Adlina and Said, Diana Suhaiza and Azman, Muhammad Irfan Raziq and Saiful Yazan, Latifah and Nurdin, Armania (2026) Differential expression of GDF-15, PSAP, and COL6A1 in prostate cancer cells and TNM plot-based clinical tissue specimens of prostate cancer Adenocarcinoma. Sains Malaysiana, 55 (4). pp. 689-705. ISSN 0126-6039

Abstract

Distinguishing aggressive from indolent prostate cancer remains a key clinical challenge. Although prostate-specific antigen (PSA) is commonly used for diagnosis, its low sensitivity and specificity limit its ability to predict tumour aggressiveness. This study aimed to investigate the expression patterns of selected protein biomarkers, including growth/differentiation factor-15 (GDF-15), prosaposin (PSAP), and collagen-α1 (VI) chain (COL6A1), in prostate cancer cells (primary and metastatic) and tumour tissue samples. The immunocytochemical (ICC) analysis showed distinct expression patterns of these proteins across different prostate cancer cell lines, with GDF-15 being highly expressed in lymph node metastatic (LNCaP) cells. In contrast, PSAP and COL6A1 were primarily expressed in primary (22Rv1) and bone metastatic (PC-3) cells. The western blot analysis confirmed differential expression of GDF-15, PSAP, and COL6A1 across prostate cancer cell lines, with GDF-15 showing higher expression in LNCaP cells, whereas PSAP and COL6A1 were highly expressed in PC-3 cells. TNMplot analysis showed that the GDF-15 gene was significantly upregulated in primary and metastatic prostate cancer tissues compared to non-tumour samples and was also markedly overexpressed in colon adenocarcinoma. Similarly, PSAP expression was elevated in primary prostate tumours relative to non-tumour tissues, with significantly higher levels observed in hepatocellular carcinoma. In contrast, COL6A1 was consistently downregulated in prostate cancer tissues and across several other malignancies. These results suggest that GDF-15 may serve as a broad-spectrum cancer biomarker, whereas PSAP and COL6A1 may be associated with disease progression and metastatic behaviour. However, further studies are needed to validate their potential clinical applications as a biomarker.


Download File

[img] Text
126341.pdf - Published Version

Download (2MB)

Additional Metadata

Item Type: Article
Subject: Multidisciplinary
Divisions: Faculty of Medicine and Health Science
DOI Number: https://doi.org/10.17576/jsm-2026-5504-09
Publisher: Penerbit Universiti Kebangsaan Malaysia
Keywords: Prostate cancer; Protein biomarkers; COL6A1; GDF-15; PSAP
Sustainable Development Goals (SDGs): SDG 3: Good Health and Well-being, SDG 10: Reduced Inequalities, SDG 9: Industry, Innovation and Infrastructure
Depositing User: Ms. Siti Radziah Mohamed@mahmod
Date Deposited: 16 Jul 2026 07:54
Last Modified: 16 Jul 2026 07:54
Altmetrics: http://www.altmetric.com/details.php?domain=psasir.upm.edu.my&doi=10.17576/jsm-2026-5504-09
URI: http://psasir.upm.edu.my/id/eprint/126341
Statistic Details: View Download Statistic

Actions (login required)

View Item View Item